Mereo BioPharma MREO
NASDAQ MREO
$0.31 +0.01 (+2.92%)
At close: Nov 11, 2026 · 4:00 PM EST

Mereo BioPharma (MREO) Convertible Debt (2023)

Updated

Mereo BioPharma (MREO) recorded Convertible Debt of $4.39 million in Q4 2023.

Analysis

Mereo BioPharma (MREO) Convertible Debt (2023) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Mereo BioPharma 47.91 Mn -79.40 Mn 800,000.00
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 4.39 Mn
API Access

Mereo BioPharma Convertible Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=convertible-debt&ticker=MREO&period=max&api_key=YOUR_API_KEY